PROGESTERONE-RECEPTOR-POSITIVE BREAST CANCER
Clinical trials for PROGESTERONE-RECEPTOR-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new PROGESTERONE-RECEPTOR-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for PROGESTERONE-RECEPTOR-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug tested for Tough-to-Treat cancers
Disease control TerminatedThis study tested an experimental drug called VLS-101 (zilovertamab vedotin) in 102 people with advanced solid tumors that had spread and stopped responding to previous treatments. The trial aimed to see if the drug could shrink tumors and was safe for cancers including breast, l…
Matched conditions: PROGESTERONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New pill tested as potential lifeline for Tough-to-Treat cancers
Disease control TerminatedThis early-stage study tested a new oral drug called NKT3447 in adults with advanced solid tumors that had progressed despite standard treatments. The main goals were to find a safe dose and see how the body processes the drug. The study was later terminated and focused on specif…
Matched conditions: PROGESTERONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC